Table II.
Association of miR levels and clinicopathological characteristics of our patients (n=50).
| Subgroup | miR-10a | miR-10b | miR-196a-5p | miR-196a-3p | miR-196b | |
|---|---|---|---|---|---|---|
| Age | ||||||
| <60 | 1.420±1.330 | 0.542 (−2.02–3.695) | −2.027±1.819 | 0.445±2.144 | −2.091±1.744 | |
| ≥60 | 1.21±0.993 | 0.985 (−2.135–2.245) | −1.845±1.999 | 1.512±2.541 | −1.696±2.149 | |
| P-value | 0.5250 | 0.1628 | 0.7423 | 0.1247 | 0.4921 | |
| Gender | ||||||
| Male | 1.181±1.303 | 0.345±1.253 | −2.101±2.043 | 1.128±2.545 | −2.102±1.628 | |
| Female | 1.406±0.976 | 1.058±1.146 | −1.756±1.799 | 1.005±2.345 | −1.640±2.267 | |
| P-value | 0.4904 | 0.0410 | 0.5288 | 0.8603 | 0.4665 | |
| Clinical stage | ||||||
| I | 1.301±1.245 | 0.678±1.255 | −1.714±1.690 | 1.032±2.603 | −1.443±1.647 | |
| II | 1.292±0.955 | 0.784±1.246 | −2.290±2.249 | 1.121±2.121 | −2.606±2.331 | |
| P-value | 0.9793 | 0.7737 | 0.3112 | 0.9017 | 0.0451 | |
| Local recurrence | ||||||
| Yes | 0.813±0.760 | 0.711±1.092 | 0.265±0.554 | 3.783±3.902 | −0.271±1.147 | |
| No | 1.340±1.162 | 0.716±1.263 | −2.112±1.866 | 0.828±2.154 | −2.000±1.984 | |
| P-value | 0.3805 | 0.9931 | 0.0153 | 0.0175 | 0.0942 | |
| Delayed LNM | ||||||
| Yes | 1.199±1.164 | 0.545±1.514 | −2.995±1.452 | 0.011±1.668 | −2.224±1.979 | |
| No | 1.349±1.140 | 0.804±1.088 | −1.369±1.896 | 1.606±2.583 | −1.666±1.982 | |
| P-value | 0.6636 | 0.4897 | 0.0033 | 0.0114 | 0.3349 | |
| Distant metastasis | ||||||
| Yes | 2.065 (−0.677–2.69) | 0.905±0.587 | −2.254±0.287 | 0.882±1.055 | −0.645±0.420 | |
| No | 1.165 (−0.655–4.58) | 0.704±1.273 | −1.900±1.967 | 1.076±2.486 | −1.939±2.016 | |
| P-value | 0.7131 | 0.7882 | 0.2976 | 0.8946 | 0.0059 | |
| Histological grade | ||||||
| G1/well | 1.178±1.190 | 0.642±1.063 | −1.529±1.854 | 1.359±2.821 | −0.96 (−7.03–2.27) | |
| G2/moderate | 1.455±1.103 | 0.95±1.461 | −2.479±1.983 | 0.495±1.602 | −2.825 (−5.155–0.81) | |
| G3/poor | 1.165 | 1.29 | −2.195 | 0.755 | −3.21 | |
| Unknown | 1.962±1.028 | −0.285±2.453 | −3.402±1.446 | 1.202±1.156 | −2.805 (−4.6–1.01) | |
| P-value | 0.7321 | 0.5453 | 0.2774 | 0.7249 | 0.5092 | |
| Mode of tumor invasion | ||||||
| 1–3 | 1.283±1.175 | 0.92 (−2.02–3.695) | −1.584±1.838 | 1.285±2.619 | −1.697±2.059 | |
| 4C-4D | 1.349±1.051 | 0.745 (−2.135–1.45) | −3.12±1.727 | 0.282±1.319 | −2.447±1.615 | |
| P-value | 0.8679 | 0.2511 | 0.0168 | 0.0918 | 0.2716 | |
| Depth of tumor | ||||||
| <5 mm | 1.289±1.081 | 0.785±1.069 | −1.832±1.941 | −1.831±2.018 | 1.081±2.483 | |
| 5 mm ≤ and <10 mm | 1.406±1.905 | −0.078±2.658 | −2.955±1.209 | −2.211±1.676 | 0.876±1.751 | |
| P-value | 0.8457 | 0.5638 | 0.2633 | 0.7173 | 0.8730 | |
| Lymphatic invasion | ||||||
| Yes | 1.364±1.347 | 0.823±1.051 | −1.039±1.308 | 1.343±3.713 | −1.643±1.413 | |
| No | 1.315±1.125 | 0.672±1.273 | −2.028±1.977 | 0.955±2.224 | −1.914±2.075 | |
| Unknown | 0.175 | 1.955 | −2.63 | 4.07 | −0.935 | |
| P-value | 0.6153 | 0.5878 | 0.4685 | 0.4339 | 0.8563 | |
| Venous invasion | ||||||
| Yes | 1.199±0.569 | 0.066±1.303 | −2.725±1.534 | 0.354±0.720 | −2.802±2.230 | |
| No | 1.309±1.189 | 0.788±1.226 | −1.832±1.939 | 1.143±2.530 | −1.757±1.950 | |
| P-value | 0.8396 | 0.2199 | 0.3264 | 0.1278 | 0.2677 | |
| Neural infiltration | ||||||
| Yes | 0.67±0.630 | −0.002±1.318 | −2.995 (−6.485–3.285) | 1.005±2.367 | −1.651±2.596 | |
| No | 1.395±1.164 | 0.769±1.221 | −2.025 (−4.735–0.725) | 1.003±2.435 | −1.907±1.953 | |
| Unknown | 0.175 | 1.955 | −2.63 | 4.07 | −0.935 | |
| P-value | 0.2493 | 0.2564 | 0.6001 | 0.4640 | 0.8660 | |
| Smoking | ||||||
| Current or past | 1.120±1.008 | 0.235±1.027 | −2.463±1.949 | 1.599±3.009 | −1.575 (−5.195–0.185) | |
| Never | 1.407±1.215 | 1.011±1.281 | −1.590±1.836 | 0.736±1.956 | −1.36 (−7.03–2.27) | |
| P-value | 0.3931 | 0.0303 | 0.1175 | 0.2749 | 0.5622 | |
| Alcohol intake | ||||||
| Current or past | 1,353±1.340 | 0.383±1.270 | −2.071±1.944 | 1.306±2.819 | −1.23 (−5.195–0.185) | |
| Never | 1.310±0.998 | 1.050±1.130 | −1.728±1.851 | 0.851±2.068 | −1.49 (−7.03–2.27) | |
| Unknown | 0.794±0.741 | 0.371±1.611 | −2.434±2.704 | 1.067±2.707 | −4.385 (−4.51–0.4325) | |
| P-value | 0.7335 | 0.1635 | 0.7459 | 0.8194 | 0.5670 |
P<0.05 indicated statistically significance. Bold values means the significant P-values (<0.05). n=50. The number of subgroups is described in Table I. The expression value of each miR is used ΔΔCq value. A Gaussian distribution of each group was tested by Shapiro-Wilk test. The homogeneity of the variances was confirmed by Levene test. For data with a Gaussian distribution, the difference between the two groups was demonstrated by Student's t-test or Welch's t-test depending on the homogeneity of the variances. For data that did not conform to a Gaussian distribution, the Mann-Whitney test was applied to compare the samples. When analyzing more than two subgroups, one-way ANOVA or Kruskal-Wallis test was used to test whether the data conformed to a Gaussian distribution. All statistical analyses were performed using the JMP software (JMP Version Pro 12; SAS Institute Inc., Cary, NC, USA). miR, micro RNA; n, number of cases; LNM, lymph node metastasis.